Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (Q33376325)
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance |
scientific article |
Statements
1 reference
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (English)
1 reference
1 reference
Philadelphia chromosome
2 August 2024
Hagop M Kantarjian
1 reference
Giuliana Alimena
1 reference
Francis Giles
1 reference
Norbert Gattermann
1 reference
Mark Litzow
1 reference
Gert J Ossenkoppele
1 reference
Kapil Bhalla
1 reference
Franck-Emmanuel Nicolini
1 reference
Stephen G O'Brien
1 reference
Ravi Bhatia
1 reference
Francisco Cervantes
1 reference
Ariful Haque
1 reference
Yaping Shou
1 reference
Debra J Resta
1 reference
Aaron Weitzman
1 reference
Philipp le Coutre
1 reference
22 August 2007
1 reference
1 reference
110
1 reference
10
1 reference
3540-3546
1 reference
Identifiers
1 reference
1 reference